On this page
COPD
COPD encompasses conditions like emphysema and chronic bronchitis, leading to breathlessness, cough, and mucus production. It primarily affects adults and is often linked to long-term exposure to irritants, with some genetic factors playing a role.
Overview
Chronic Obstructive Pulmonary Disease (COPD) is a collective term for a group of progressive lung diseases that block airflow and make it increasingly difficult to breathe. This condition typically includes emphysema and chronic bronchitis, both of which damage the lungs over time [PMID:33678082]. Emphysema involves the destruction of the tiny air sacs (alveoli) in the lungs, reducing their elasticity. Chronic bronchitis is characterised by long-term inflammation of the airways, leading to a persistent cough and overproduction of mucus. COPD affects many adults in the UK, often developing gradually over years.
Symptoms & clinical features
The symptoms of COPD usually worsen over time. Initial signs may be mild, such as occasional shortness of breath and a cough, which may be dismissed as part of ageing or a smoker's cough. As the condition progresses, individuals often experience persistent breathlessness, particularly during physical activity, and a chronic cough that may produce clear, white, yellow, or greenish mucus [PMID:33678082]. Wheezing (a whistling sound during breathing) and chest tightness are also common. In some cases, severe COPD can lead to swelling in the ankles, feet, or legs, and fatigue due to the increased effort of breathing.
Video: Genetics 101
Affected organs
COPD primarily affects the lungs and airways. The small airways and air sacs within the lungs become damaged and inflamed. This damage reduces the lungs' ability to exchange oxygen and carbon dioxide effectively, impacting overall respiratory function. Over time, the strain on the lungs can also affect other body systems, including the heart, as the heart has to work harder to pump blood through the damaged lungs.
Risks & severity
COPD is a progressive condition, meaning its severity typically increases over time. The main risk factor is long-term exposure to irritants, most notably cigarette smoke, but also passive smoke, air pollution, and occupational dusts and chemicals [PMID:35338604]. While most cases are linked to environmental factors, certain genetic factors can increase an individual's susceptibility. The natural history of COPD varies greatly; some people experience mild symptoms for many years, while others face a more rapid decline in lung function. The exact prevalence of COPD in adults is estimated to be around 10%.
Genetic causes
While environmental factors are the primary cause, genetic predispositions can influence an individual's susceptibility to COPD. The inheritance pattern for COPD is considered polygenic or complex, meaning multiple genes, along with environmental factors, contribute to the risk of developing the condition. Genes such as SERPINA1 encode for alpha-1 antitrypsin, a protein important for protecting the lungs from damage caused by inflammation. Pathogenic variants in SERPINA1 can lead to alpha-1 antitrypsin deficiency, a significant genetic risk factor for early-onset emphysema [PMID:31256384]. Other genes, such as CHRNA3, which is involved in nicotine addiction, may also play a role by influencing smoking behaviour, thereby indirectly affecting COPD risk. However, carrying a genetic variant does not guarantee development of COPD, and many individuals with environmental risk factors do not develop the condition.
Inheritance pattern
COPD generally follows a polygenic or complex inheritance pattern. This means that unlike conditions caused by a single gene, COPD risk is influenced by a combination of multiple genetic factors interacting with environmental exposures. For most individuals, there isn't a simple 'inheritable' gene for COPD that is passed down in a clear pattern. However, certain genetic predispositions, like alpha-1 antitrypsin deficiency linked to SERPINA1, can significantly increase risk and may be inherited in an autosomal recessive manner. In such cases, an individual must inherit two copies of the altered gene (one from each parent) to be at increased risk of disease. For the majority, genetic components contribute to an overall susceptibility rather than causing the disease directly.
Diagnosis & testing
Diagnosing COPD typically involves a review of symptoms, a physical examination, and a lung function test called spirometry. Spirometry is a simple breathing test that measures how much air an individual can breathe out and how quickly [PMID:35338604]. This test is crucial for confirming the diagnosis and assessing the severity of airflow obstruction. In specific cases, blood tests to check for alpha-1 antitrypsin deficiency (R-code R116), chest X-rays, or CT scans may be performed to rule out other conditions or assess lung damage. Referral for such tests often comes from a GP or respiratory specialist. Genetic testing for specific genes like SERPINA1, which falls under NHS Genomic Medicine Service testing criteria for certain indications, may be organised by clinical genetics services following specialist consultation.
Management & lifestyle
Managing COPD aims to alleviate symptoms, reduce exacerbations, and improve quality of life. This typically involves a multi-faceted approach, often guided by a GP or respiratory specialist within the NHS. Lifestyle changes, such as stopping smoking, are paramount. Medications, including bronchodilators to open airways and steroids to reduce inflammation, may be prescribed. Pulmonary rehabilitation programmes, offering exercise, education, and support, are often recommended [PMID:33678082]. In advanced stages, oxygen therapy or even surgical interventions might be considered. Genetic counselling may be helpful for individuals with specific genetic factors, such as alpha-1 antitrypsin deficiency, to understand implications and family risks.
UK care pathway
In the UK, suspected COPD is typically investigated by a General Practitioner (GP) who may refer individuals to a respiratory specialist for further assessment and management. Genetic testing, particularly for conditions like alpha-1 antitrypsin deficiency (R-code R116), is available through the NHS Genomic Medicine Service (GMS) pathways. Referrals for GMS testing are usually made by a clinical geneticist or a specialist clinician. Genetic counsellors are available to provide information and support to individuals and families regarding genetic conditions and testing options.
Frequently asked questions
Can COPD be cured?
Currently, there is no cure for COPD, as the lung damage is typically permanent. However, treatments and lifestyle changes can help manage symptoms, slow disease progression, and improve quality of life. Early diagnosis and intervention are important.
Is COPD always caused by smoking?
While smoking is the leading cause of COPD, it is not the only one. Other risk factors include exposure to passive smoke, air pollution, occupational dusts and chemicals, and certain genetic factors like alpha-1 antitrypsin deficiency. Some individuals who have never smoked can still develop COPD.
What is alpha-1 antitrypsin deficiency and how does it relate to COPD?
Alpha-1 antitrypsin deficiency is a genetic condition where the body does not produce enough of a protective protein, alpha-1 antitrypsin, which helps shield the lungs from damage. Individuals with this deficiency are at a significantly increased risk of developing emphysema, a type of COPD, often at a younger age.
What can I do to prevent COPD?
The most effective way to prevent COPD is to avoid smoking and exposure to passive smoke. Minimising exposure to air pollution and occupational dusts or chemicals can also reduce risk. For those with genetic predispositions like alpha-1 antitrypsin deficiency, avoiding these environmental triggers is even more crucial.
How does COPD affect daily life?
COPD can significantly impact daily life due to symptoms like breathlessness and fatigue. Simple activities can become challenging. However, with appropriate management, including medication, exercise, and support, many individuals can maintain an active and fulfilling life.
References
- Calverley PMA, Walker PP. Contemporary Concise Review 2022: Chronic obstructive pulmonary disease. Respirology (Carlton, Vic.). 2023. PMID: 36922031
- Thawanaphong S, Nair P. Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease. Respirology (Carlton, Vic.). 2025. PMID: 40437348
- Santiago Díaz C, Medrano FJ, Muñoz-Rivas N. COPD and cardiovascular risk. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2025. PMID: 39909770
- Polman R, Hurst JR, Uysal OF. Cardiovascular disease and risk in COPD: a state of the art review. Expert review of cardiovascular therapy. 2024. PMID: 38529639
- Lai HC, Lin TL, Chen TW. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut. 2022. PMID: 33687943
- Barnes PJ. Asthma-COPD coexistence. The Journal of allergy and clinical immunology. 2024. PMID: 38866207
- Christenson SA. COPD Phenotyping. Respiratory care. 2023. PMID: 37353326
- Papi A, Alfano F, Bigoni T. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses. Archivos de bronconeumologia. 2024. PMID: 38555190